15 August 2017 - - US-based biopharmaceutical company Omeros Corp. (NASDAQ: OMER) has commenced a registered underwritten public offering of 3m shares of its common stock, the company said.

In addition, Omeros has granted the underwriter a 30-day option to purchase up to 450,000 additional shares of its common stock.

Cantor Fitzgerald and Co. is acting as the bookrunner for the offering.

Omeros plans to use the net proceeds of the offering for general corporate purposes, including expenses related to funding research and development for its OMS721 programs and clinical trials, preclinical studies, manufacturing and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions.

The company may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.